Demarteau N - Search Results

1

Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines.

Quiambao B, Varghese L, Demarteau N, Sengson RF, Javier J, Mukherjee P, Manio LC, Preiss S. Quiambao B, et al. Among authors: demarteau n. Int J Infect Dis. 2020 Aug;97:38-46. doi: 10.1016/j.ijid.2020.05.062. Epub 2020 May 22. Int J Infect Dis. 2020. PMID: 32450291 Free article.

2

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P. Demarteau N, et al. Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15. Vaccine. 2013. PMID: 23777952 Free article.

3

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

Li X, Stander MP, Van Kriekinge G, Demarteau N. Li X, et al. Among authors: demarteau n. BMC Infect Dis. 2015 Dec 11;15:566. doi: 10.1186/s12879-015-1295-z. BMC Infect Dis. 2015. PMID: 26652918 Free PMC article.

4

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G. Demarteau N, et al. Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12. Value Health. 2012. PMID: 22867770 Free article.

5

Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?

Van Bellinghen LA, Dimitroff A, Haberl M, Li X, Manton A, Moeremans K, Demarteau N. Van Bellinghen LA, et al. Among authors: demarteau n. Hum Vaccin Immunother. 2018;14(9):2263-2273. doi: 10.1080/21645515.2018.1474315. Epub 2018 Jun 22. Hum Vaccin Immunother. 2018. PMID: 29771574 Free PMC article.

6

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. Demarteau N, et al. Int J Public Health. 2011 Apr;56(2):153-62. doi: 10.1007/s00038-010-0216-6. Epub 2010 Nov 26. Int J Public Health. 2011. PMID: 21110060 Free PMC article.

7

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N. Gomez JA, et al. Among authors: demarteau n. BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222. BMC Public Health. 2014. PMID: 25424716 Free PMC article.

8

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?

Bonanni P, Gabutti G, Demarteau N, Boccalini S, La Torre G. Bonanni P, et al. Among authors: demarteau n. BMC Infect Dis. 2015 Sep 17;15:377. doi: 10.1186/s12879-015-1067-9. BMC Infect Dis. 2015. PMID: 26381489 Free PMC article.

9

Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Konno R, et al. Among authors: demarteau n. Int J Gynecol Cancer. 2010 Apr;20(3):385-92. doi: 10.1111/IGC.0b013e3181d189b8. Int J Gynecol Cancer. 2010. PMID: 20375802

10

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.

Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, Hahl J. Torvinen S, et al. Among authors: demarteau n. J Med Econ. 2010;13(2):284-94. doi: 10.3111/13696998.2010.485951. J Med Econ. 2010. PMID: 20482244 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters